ArticleDiscover oncology2025
Effects of Coronin 2A on prognosis and immune microenvironment in tumor patients: a knowledge map of the novel biomarker via bioinformatics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRecent studies have highlighted the vital role of CORO2A in tumor proliferation, migration, and metastasis. However, its immunological and prognostic significance across various cancers remains poorly understood.
methodsWe conducted an analysis of CORO2A expression patterns, prognostic value, and immunological associations across multiple cancers using data from TCGA, Kaplan-Meier Plotter, PrognoScan, TISIDB databases, as well as GEPIA2, TIMER2, and Xiantao Academic Web. Additionally, CORO2A-associated gene enrichment analysis was performed using STRING, GEPIA2, GO, DAVID, and KEGG datasets.
resultsOur findings revealed elevated CORO2A expression in most cancers compared to corresponding normal tissues. Lower CORO2A expression was associated with longer OS (overall survival), DFS (disease-free survival), RFS (recurrence-free survival), and DMFS (distant metastasis-free survival) in some cancer types, while the opposite trend was observed in others. CORO2A expression showed significant correlations with the abundance of tumor-infiltrating lymphocytes, immunomodulators, chemokines, as well as the infiltration levels of CAF (cancer-associated fibroblasts) and MDSC (myeloid-derived suppressor cells) across various cancers. We also found that the expression of CORO2A closely related to the markers of immune cell in LUAD and LUSC. Enrichment analysis revealed that CORO2A-related genes were primarily involved in actin filament organization, cell leading edge dynamics, actin binding, and pathways related to pathogenic Escherichia coli infection.
conclusionOur pan-cancer study provided a relatively comprehensive understanding of the oncogenic roles of CORO2A across different tumor types. We identified CORO2A as a prognostic biomarker and demonstrated its correlation with immune cell infiltration in pan-cancer contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.